All items in the Healthy Skepticism Library
All the 20545 items in the Healthy Skepticism Library are listed below in order of publication date with the most recent at the top. There are 100 items per page.
Page 194 of 206 pages ‹ First < 192 193 194 195 196 > Last ›
HSL9649
Kushner D.
Don't advertise Rx drugs to public, mfrs are urged
American Druggist 1986 Mar;193:126, 128, 130, 132
HSL9662
To what extent should pharmaceutical houses advertise to the public?
Pharmacy Times 1986 Mar;52:86-88, 90, 93
HSL9661
Robinson B.
Consumer Rx ads viewed warily by pharmacists
Drug Topics 1986 Feb 17;130:94, 96
HSL9659
Robinson B.
Consumer Rx ads edge closer to reality
Drug Topics 1986 Feb 3;130:42
HSL3385
Re: the promotion of ibuprofen syrup
1986 Feb;
HSL9638
Radoczy G.
Formulae Normales
Gyogyszereszet 1986 Feb;30:59-62
HSL9656
Cramer PK.
Measuring the marketing clout of postmarketing clinical studies
Pharmaceutical Executive 1986 Feb;6:54-55, 57
HSL9660
To keep drugs cost effective, industry told to look at compliance
American Pharmacy 1986 Feb;26:7
HSL3355
Mahood CB, Rothwell RP, Holford N.
Slow-release theophylline (THEO-24)
N Z Med J. 1986 Jan 22;99:(794):21
HSL9653
Debenedette V.
CBS ready for Rx ads
Med Advert News 1986 Jan 15;5:1, 37-38
HSL861
Mansfield P.
Phenylbutazone.
Med J Aust 1986 Jan 6;144:(1):55
HSL20475
Mansfield PR
Phenylbutazone
Medical Journal of Australia 1986 Jan 6;144:55
HSL3363
Morris LA, Brinberg D, Klimberg R, Rivera C, Millstein LG.
The attitudes of consumers toward direct advertising of prescription drugs.
Public Health Rep 1986 Jan-Feb;101:(1):82-9
HSL3384
How physicians feel about Rx drug product ads beamed at the public
Pharmacy Times 1986 Jan;52:(1):85-88, 91-92
HSL8351
How physicians feel about Rx drug product ads beamed at the public
Pharmacy Times 1986 Jan;52:85-88, 91-92
HSL9594
Pollock CL.
Advertising prescription drugs to the public: who benefits?
DO 1986 Jan;27:111-116
HSL9597
Sandrick K.
Generics: moving in on the prescription drug market
DO 1986 Jan;27:85-88
HSL9650
Discriminatory pricing: attacking prescription drug diversion at its source
National Association of Retail Druggists Journal 1986 Jan;108:16-18, 28
HSL2059
Goldman R, Montagne M.
Marketing 'mind mechanics': decoding antidepressant drug advertisements.
Soc Sci Med 1986;22:(10):1047-58
HSL3315
Bayer UK Ltd suspended over actions by representatives
Pharmaceutical Journal 1986;237:821-822
HSL3316
Charges against Roussel Laboratories concerning advertisements
Lancet 1986;1:112
HSL3317
Congressional panel wants to ban drug samples
Canadian Medical Association Journal 1986;134:1302
HSL3318
Need for a rational drugs policy
Lancet 1986;1:262
HSL3320
Akin GM.
The ethics of pharmaceutical promotion
New England Journal of Medicine 1986;315:590
HSL3321
Anand MP.
Marketing drugs in the Third World
Lancet 1986;2:222
HSL3322
Bader M.
Advertising prescription drugs to the public
New England Journal of Medicine 1986;314:523
HSL3323
Bearn AG.
Should a drug company employee edit a medical journal?
Lancet 1986;1:974
HSL3324
Bhattacharjee PK.
Marketing drugs in the Third World
Lancet 1986;2:576
HSL3325
Blum AL, Chalmers TC, Deutsch E, Koch-weser J, Langman M, Rosen A, Tygstrup N, Zentgraf R.
Differing attitudes of industry and academia towards controlled clinical trials
European Journal of Clinical Investigation 1986;16:455-460
HSL3326
Blumenthal D, Gluck M, Louis KS, Stoto MA, Wise D.
University-industry research relationships in biotechnology: implications for the university
Science 1986;232:1361-1366
HSL3328
Burley DM.
Should a drug company employee edit a medical journal?
Lancet 1986;1:(801):
HSL3329
Cairns L.
Offensive advertising?
New Zealand Medical Journal 1986;99:641-642
HSL3330
Guidelines for drug-company-supported CME
Canadian Medical Association Journal 1986;135:384A
HSL3332
Cohen RL.
Drug companies and journal supplements
Lancet 1986;1:1157
HSL3333
Collins GL.
Prescription drug advertising: a medical view
Journal of Pharmaceutical Marketing & Management 1986;1:(2):19-22
HSL3334
Comanor WS.
The political economy of the pharmaceutical industry.
J Econ Lit 1986;24:(3):1178-1217
HSL3335
Drugs and the Third World: chloroform sale and hazards—a Malaysian study
Consumers’ Association of Penang 1986;
HSL3336
Cramer R.
Information responsibilities of generic drug companies
American Journal of Hospital Pharmacy 1986;43:1674-1675
HSL3338
Dingell JD.
Advertising prescription drugs to the public
New England Journal of Medicine 1986;314:524
HSL3340
Feather KR.
Direct to the consumer advertising—how close can we come?
Journal of Pharmaceutical Marketing & Management 1986;1:(2):67-71
HSL3342
Greenhalgh T.
Marketing drugs in the Third World
Lancet 1986;2:222
HSL3343
Henderson AM.
The CBS consumer model
Journal of Pharmaceutical Marketing & Management 1986;1:(2):7-11
HSL3345
Kerr HD, Brobny EC.
Advertising prescription drugs to the public
New England Journal of Medicine 1986;314:523-524
HSL3346
Lapinski F.
Omission of women and black physicians from Journal ads
New England Journal of Medicine 1986;314:653
HSL3350
Lavizzo-mourey R.
Medications and the elderly
Journal of Pharmaceutical Marketing & Management 1986;1:(2):45-50
HSL3351
Lee A.
Marketing drugs in the Third World
Lancet 1986;2:222
HSL3352
Leigh AP.
Should a drug company employee edit a medical journal?
Lancet 1986;1:974
HSL3353
Lipton C.
Consumer advertising and pharmaceuticals: a happy marriage?
Journal of Pharmaceutical Marketing & Management 1986;1:(2):23-28
HSL3354
Mac Sheoin T.
Unethical behavior in an ethical industry? Critical coverage of the pharmaceutical industry, 1983-1984
International Journal of Health Services 1986;16:141-162
HSL3356
Mamdani M, Walker G.
Essential drugs in the developing world
Health Policy and Planning 1986;1:187-201
HSL3357
Masson A, Rubin PH.
Advertising prescription drugs to the public
New England Journal of Medicine 1986;314:524
HSL3358
Masson A, Rubin PH.
Warning: brief summaries may be hazardous to your health (and wealth) or the real issues in prescription drug advertising to consumers
Journal of Pharmaceutical Marketing & Management 1986;1:(2):29-43
HSL3360
McGovern I.
Advertising and benzodiazepines
Medical Journal of Australia 1986;145:179
HSL3361
McMahon FG.
Advertising prescription drugs to the public
New England Journal of Medicine 1986;314:524
HSL3362
Moench EA.
The Boots advertising campaign
Journal of Pharmaceutical Marketing & Management 1986;1:(2):51-55
HSL3364
Morris LA, Brinberg D, Klimberg R, Millstein L, Rivera C.
Consumer attitudes about advertisements for medicinal drugs.
Soc Sci Med 1986;22:(6):629-38
HSL3367
O’brien M.
Advertising prescription drugs to the public
New England Journal of Medicine 1986;314:523
HSL3368
Perkin RL.
The pharmaceutical industry
Canadian Family Physician 1986;32:2013
HSL3369
Rockwell T.
The Lifetime experience with prescription drug advertising exposed to consumers
Journal of Pharmaceutical Marketing & Management 1986;1:(2):13-18
HSL3370
Roseman EP.
Checking the scorecard
Medical Marketing & Media 1986;21:(10):40, 42, 44
HSL3372
Schueler KR.
Direct-to-consumer promotion
Journal of Pharmaceutical Marketing & Management 1986;1:(2):57-65
HSL3373
Silverman M, Lee PR, Lydecker M.
Drug promotion: the Third World revisited.
Int J Health Serv 1986;16:(4):659-67
HSL3376
St. George
Effects of medical research on life expectancy
Lancet 1986;2:517
HSL3378
Stavem P.
Should a drug company employee edit a medical journal?
Lancet 1986;1:684
HSL3380
Turner J.
Antibiotic conference cancelled for second time
Lancet 1986;1:333
HSL3381
Vener AM, Krupka LR.
Over-the-counter drug advertising in gender oriented popular magazines.
J Drug Educ 1986;16:(4):367-81
HSL3383
Woods D.
PMAC to spend almost $1 million annually to reach “stakeholders”
Canadian Medical Association Journal 1986;134:1387, 1389
HSL3389
Rothschild M.
Death by prescription
The Progressive 1986;50:(6):18, 20-22
HSL3409
Collier J.
Promotion of medicines—the failure of regulation
Medicine in Society 1986;12:(3):8-10
HSL9061
McDonnell K
Adverse Effects - Women and the Pharmaceutical Industry
: Canadian Scholars Press 1986
http://www.amazon.ca/Adverse-effects-Women-pharmaceutical-industry/dp/0889611084
HSL9609
Laroche M, Rosenblatt J, Wahler L, Bliemel F.
Economic considerations for dispensing pharmacists: the impact of price-quality evaluations on brand categorization.
J Pharm Mark Manage 1986 Fal;1:(1):41-60
HSL9632
Von-breitenbach G.
German pharmaceutical industry abroad. Part 2
Drugs Made in Germany 1986;29:(2):63-67
HSL9636
Lowenthal W, Klein WS 3rd, Overton CP.
Thinking about ethical dilemmas in pharmacy.
Am J Pharm Educ 1986 Sum;50:(2):161-4
HSL13283
Holbrook MB, Lehmann DR, O'Shaughnessy J.
Using versus Choosing: The Relationship of the Consumption Experience to Reasons for Purchasing.
European Journal of Marketing 1986;20:(8):49-62
http://www.ingentaconnect.com/content/mcb/007
HSL16525
Bowman MA
The impact of drug company funding on the content of continuing medical education.
Möbius 1986;6:(1):66-69
HSL16714
Wolfe S
Letter to the Editor on safety of piroxicam
Lancet 1986;8510:808-809
HSL9668
Robinson B.
PMA chief sees pattern of cooperation with pharmacy
Drug Topics 1985 Dec 9;129:12-13
HSL3313
Re: the promotion of Entero-Sediv
1985 Dec 01;
HSL9667
Jacknowitz AI.
Inactive ingredients in medications
US Pharmacist 1985 Dec;10:37, 58
HSL9669
Shepherd MD.
Managing your pharmacy: targeting your elderly market
American Druggist 1985 Dec;192:49, 51-53, 56
HSL9658
Dunn WR, Hamilton DD, Lilja J.
Pharmacy in Sweden
Pharmaceutical Journal 1985 Nov 30;235:714-715
HSL9663
Pack size changes and six month delay planned
Pharmaceutical Journal 1985 Nov 30;235:712
HSL3310
Re: the promotion of anabolic steroids for children
1985 Nov 01;
HSL3311
FDA withdraws moratorium on direct-to-consumer advertising
American Pharmacy 1985 Nov 01;25:(11):9-11
HSL3312
Teplitsky B.
A 30-year trend: what chief pharmacists think about detailers.
Pharm Times 1985 Nov;51:(11):83-92
HSL8350
Cronin WF.
Marketing to the new decision makers
Pharmaceutical Executive 1985 Nov;5:48, 50, 53
HSL8353
Printer technology: the new impact
ComputerTalk for the Pharmacist 1985 Nov;5:16-19, 22-25
HSL8367
Robinson B.
Rx-to-consumer advertising debate starts up again
Drug Topics 1985 Oct 7;129:20, 22
HSL3281
Logan AG, Larochelle P.
Diuretic-induced hypokalemia in hypertension.
CMAJ 1985 Oct 1;133:(7):639-40
HSL3289
Osiobe SA.
Sources of information for biomedical decision-making.
Methods Inf Med 1985 Oct;24:(4):225-9
HSL3309
Morris LA, Ruffner M, Klimberg , R .
Warning disclosures for prescription drugs
Journal of Advertising Research 1985 Oct-Nov;25:(2):25-32
HSL8357
Buono LC, Hartmann JP.
Hybrids new OTC option
Pharmaceutical Executive 1985 Oct;5:46, 48, 52
HSL8358
Muglia D.
Hispanic U.S.A.-undiscovered market
Pharmaceutical Executive 1985 Oct;5:66, 68, 70
HSL8369
Changes in drug marketing bode well for pharmacy
American Pharmacy 1985 Oct;22
HSL9645
Industrial drug research in seven nations: key findings of a recent OHE/MPS study on the drug industry in seven OECD-countries
Drugs Made in Germany 1985 Oct-Dec;25:153-158, 160
HSL3275
Harvey K, Darvall L.
Australian pharmaceutical advertising: a critique.
Med J Aust 1985 Sep 30;143:(7):272-4
HSL3294
Weissel JR.
Australian pharmaceutical advertising: the industry's view.
Med J Aust 1985 Sep 30;143:(7):274-5
HSL20511
de Lacey G, Record C, Wade J
How accurate are quotations and references in medical journals?
BMJ 1985 Sep 28;291:884
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1416756/
HSL3213
Relman AS.
Dealing with conflicts of interest.
N Engl J Med 1985 Sep 19;313:(12):749-51
HSL862
Mansfield P.
Phenylbutazone.
Med J Aust 1985 Sep 2;143:(5):219-20
Page 194 of 206 pages ‹ First < 192 193 194 195 196 > Last ›
